Back to top

Amarin (AMRN) Gains But Lags Market: What You Should Know

Read MoreHide Full Article

Amarin (AMRN - Free Report) closed at $22.98 in the latest trading session, marking a +0.48% move from the prior day. The stock lagged the S&P 500's daily gain of 0.56%. Meanwhile, the Dow gained 0.76%, and the Nasdaq, a tech-heavy index, lost 0.38%.

Prior to today's trading, shares of the biopharmaceutical company had gained 12.72% over the past month. This has outpaced the Medical sector's loss of 6.31% and the S&P 500's loss of 6.76% in that time.

AMRN will be looking to display strength as it nears its next earnings release, which is expected to be February 26, 2019. The company is expected to report EPS of -$0.14, down 75% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $70.87 million, up 31.55% from the prior-year quarter.

AMRN's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $227.47 million. These results would represent year-over-year changes of -68% and +25.6%, respectively.

Any recent changes to analyst estimates for AMRN should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMRN is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 87, which puts it in the top 34% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amarin Corporation PLC (AMRN) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in